Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Åsa Rembratt"'
Autor:
null European Biopharmaceutical Enterprises, Keith Watson, Virginia Acha, Alexander Roediger, Åsa Rembratt, Edward Hume, Fabio Bisordi, Marloes van Bruggen
Publikováno v:
Generics and Biosimilars Initiative Journal. 3:188-192
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ecd137c03a3ab3007597539a0e3776ad
https://doi.org/10.5639/gabij.2014.0304.043
https://doi.org/10.5639/gabij.2014.0304.043
Autor:
Justo García de Yébenes, Jeremy Bright, Bernhard Landwehrmeyer, Ralf Reilmann, Anne Elizabeth Rosser, Allan Prang, Åsa Rembratt, Jelena Ivkovic, Ferdinando Squitieri
Publikováno v:
Neurology. 80:1086-1094
Objective: To assess the 1-year safety profile of the dopaminergic stabilizer pridopidine in patients with Huntington disease. Methods: Patients received pridopidine 45 mg/day for 4 weeks then pridopidine 90 mg/day for 22 weeks in this 6-month open-l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f56b7e8ecea892b74f8a7bda72360828
https://doi.org/10.1212/wnl.0b013e3182886965
https://doi.org/10.1212/wnl.0b013e3182886965
Publikováno v:
BJU International. 92:726-730
OBJECTIVE To investigate the association between nocturia and selected concomitant diseases and medications in a community-dwelling elderly population. SUBJECTS AND METHODS Data were obtained with a validated questionnaire mailed to all inhabitants a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f6048f25dd0c0a55d8e344b40f4b6956
https://doi.org/10.1046/j.1464-410x.2003.04467.x
https://doi.org/10.1046/j.1464-410x.2003.04467.x
Publikováno v:
BJU International. 91:642-646
OBJECTIVE To investigate the short-term safety of desmopressin in elderly patients with nocturia, with special focus on the risk of hyponatraemia, and to assess the short-term effects on urine output, sleep and voiding patterns. PATIENTS AND METHODS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::099481eac61025781f80684b699a2e4a
https://doi.org/10.1046/j.1464-410x.2003.04170.x
https://doi.org/10.1046/j.1464-410x.2003.04170.x
Publikováno v:
BJU International. 91:45-50
OBJECTIVE To evaluate differences between elderly people with and without nocturia (waking up in the night to void) in terms of voiding habits, urine production and voided volumes. SUBJECTS AND METHODS Nocturics (≥ two voids/night) and non-nocturic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae2bc306c22b1704ffa9c8f7a2c49564
https://doi.org/10.1046/j.1464-410x.2003.03079.x
https://doi.org/10.1046/j.1464-410x.2003.03079.x
Publikováno v:
BJU International. 90:18-20
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::67f5e482c7113447d308d4ff7b7f0bbd
https://doi.org/10.1046/j.1464-410x.90.s3.5.x
https://doi.org/10.1046/j.1464-410x.90.s3.5.x
Autor:
Roger A. Barker, Markus Magnet, Åsa Rembratt, Ralf Reilmann, Anne Elizabeth Rosser, Joakim Tedroff, Carsten Saft, Ferdinando Squitieri, Alastair Sword, Justo García de Yébenes, Bernhard Landwehrmeyer
Publikováno v:
The Lancet. Neurology. 10(12)
Summary Background Huntington's disease is a progressive neurodegenerative disorder, characterised by motor, cognitive, and behavioural deficits. Pridopidine belongs to a new class of compounds known as dopaminergic stabilisers, and results from a sm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18c1a93be35bf7b50c7098e7e72135ff
https://pubmed.ncbi.nlm.nih.gov/22071278
https://pubmed.ncbi.nlm.nih.gov/22071278
Publikováno v:
Neurourology and Urodynamics; 25(2), pp 105-109 (2006)
Aims: To explore the incidence, severity, time course, and risk factors of clinically significant hyponatremia in desmopressin treatment for nocturia. Methods: Data from three multi-center phase 111 trials were pooled. Hyponatremia was categorised as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48df95a3c3d51947c44c18d4724541a9
https://lup.lub.lu.se/record/147765
https://lup.lub.lu.se/record/147765
Autor:
Jens Peter Nørgaard, Jens Christian Djurhuus, Åsa Rembratt, Charlotte Graugaard-Jensen, Thomas Senderovitz
Publikováno v:
European journal of clinical pharmacology. 60(6)
To investigate (1) the pharmacokinetic and pharmacodynamic profiles of desmopressin in men from an age group with a high incidence of nocturia; and (2) circadian variation in the pharmacokinetic parameters.The study had an open, randomised, four-way
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::beed8eae06644bd40c2f1dfbf59d2447
https://pubmed.ncbi.nlm.nih.gov/15197520
https://pubmed.ncbi.nlm.nih.gov/15197520
Autor:
Anne Elizabeth Rosser, R Reilmann, Georg Bernhard Landwehrmeyer, A Sword, Ferdinando Squitieri, Joakim Tedroff, J Garcia de Yebenes, Åsa Rembratt
Publikováno v:
Journal of Neurology, Neurosurgery & Psychiatry. 81:A49-A49
Background Pridopidine is a dopaminergic stabiliser, a new class of compound that stabilises the dopamine system and has the potential to treat neurological and psychiatric disorders characterised by altered dopamine transmission. Aims To investigate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::25c16b5c8193c28a388acf00abbb824a
https://doi.org/10.1136/jnnp.2010.222687.5
https://doi.org/10.1136/jnnp.2010.222687.5